The Dermatomyositis market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Dermatomyositis: An Overview
Idiopathic inflammatory myopathies are a heterogeneous group of connective tissue disorders characterized by progressive muscle weakness. The cause of the idiopathic inflammatory myopathies remains undetermined. All are thought to be due to immune system abnormalities leading to inflammation in muscle and other tissues. IIM is the umbrella term that includes dermatomyositis (DM), polymyositis (PM), overlap myositis (OM), sporadic inclusion body myositis (IBM), and necrotizing autoimmune myopathy (NAM), also known as immune-mediated necrotizing myopathy.
Dermatomyositis is a rare inflammatory disease with characteristic cutaneous findings and varying amounts of systemic involvement; it occurs in both juvenile and adult forms. Adult and juvenile Dermatomyositis share the hallmark features of pathognomic skin rash and muscle inflammation but are heterogeneous disorders with various additional disease features and complications.
Dermatomyositis Market Key Facts
In 2021, the total Dermatomyositis market size was ~USD 180 million in the 7MM, which is expected to rise during the study period (2019–2032).
The total Dermatomyositis market size in the United States was ~USD 130 million in 2021.
In 2021, the total Dermatomyositis prevalent case was ~61,200 cases in the 7MM, which are expected to grow by 2032.
As per DelveInsight’s estimates, in the 7MM, the highest number of total prevalent cases of Dermatomyositis were observed in the United States, with ~35,300 cases in 2021, estimated to increase by 2032 at a moderate CAGR.
The total prevalent cases of Dermatomyositis in EU4 and the UK comprised ~18,000 cases in 2021 and are projected to increase by 2032 at a moderate CAGR during the forecast period (2021–2032).
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Dermatomyositis market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Dermatomyositis market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.
Dermatomyositis Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Dermatomyositis Epidemiology, Segmented by –
Total Prevalent Cases of Dermatomyositis
Total Diagnosed Prevalent Cases of Dermatomyositis
Gender-specific Diagnosed Prevalent Cases of Dermatomyositis
Age-specific Diagnosed Prevalent Cases of Dermatomyositis
Severity-specific Diagnosed Prevalent Cases of Dermatomyositis
Classification-Specific Diagnosed Prevalent Cases of Dermatomyositis
Chronicity-Specific Diagnosed Prevalent Cases of Dermatomyositis
Co-morbidity-Specific Diagnosed Prevalent Cases of Dermatomyositis
Treated cases of Dermatomyositis
Dermatomyositis Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Dermatomyositis market or expected to be launched during the study period. The analysis covers the Dermatomyositis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Dermatomyositis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Dermatomyositis Market Will Evolve and Grow by 2032 @
Dermatomyositis Therapeutics Analysis
The goal of treatment is to reduce inflammation and vasculitis, invariably minimize symptomatology, and improve the patient’s quality of life. To achieve this goal, a treatment regimen must be initiated early in the disease process and will require an interprofessional approach to achieve the goal of therapy. Treatment of Dermatomyositis involves the administration of steroids. In addition, a high dose of prednisolone must be initiated early to improve muscle weakness. To further improve the Dermatomyositis treatment scenario, globally, several key companies are actively working in the therapeutics market.
The Leading Companies in the Dermatomyositis Therapeutics Market Include:
And Many Others
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Dermatomyositis Competitive Intelligence Analysis
4. Dermatomyositis Market Overview at a Glance
5. Dermatomyositis Disease Background and Overview
6. Dermatomyositis Patient Journey
7. Dermatomyositis Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Dermatomyositis Treatment Algorithm, Current Treatment, and Medical Practices
9. Dermatomyositis Unmet Needs
10. Key Endpoints of Dermatomyositis Treatment
11. Dermatomyositis Marketed Products
12. Dermatomyositis Emerging Drugs and Latest Therapeutic Advances
13. Dermatomyositis Seven Major Market Analysis
14. Attribute Analysis
15. Dermatomyositis Market Outlook (In US, EU5, and Japan)
16. Dermatomyositis Access and Reimbursement Overview
17. KOL Views on the Dermatomyositis Market
18. Dermatomyositis Market Drivers
19. Dermatomyositis Market Barriers
21. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
Other Trending Healthcare Reports By DelveInsight
“Dermatomyositis – Pipeline Insight, 2023,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Dermatomyositis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products by stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States